{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:33:12Z","timestamp":1778394792225,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260365"],"award-info":[{"award-number":["82260365"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372315"],"award-info":[{"award-number":["82372315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Kunlun Elite, High-End Innovation and Entrepreneurship Talents of Qinghai Province","award":["2021 No. 13"],"award-info":[{"award-number":["2021 No. 13"]}]},{"name":"Basic Basic Research Program of Qinghai Province - Applied Basic Research Program","award":["2023-ZJ-716"],"award-info":[{"award-number":["2023-ZJ-716"]}]},{"name":"The guiding project of Qinghai Provincial Health and Family Planning Commission","award":["2018-wjzdx17"],"award-info":[{"award-number":["2018-wjzdx17"]}]},{"name":"Qinghai Provincial People's Hospital In-Hospital Issues","award":["2023-qhsrmyy-08"],"award-info":[{"award-number":["2023-qhsrmyy-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The composition of the bone marrow immune microenvironment in patients with acute myeloid leukaemia (AML) was analysed by single-cell sequencing and the evolutionary role of different subpopulations of T cells in the development of AML and in driving drug resistance was explored in conjunction with E3 ubiquitin ligase-related genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To elucidate the mechanisms underlying AML-NR and Ara-C resistance, we analyzed the bone marrow immune microenvironment of AML patients by integrating multiple single-cell RNA sequencing datasets. When compared to the AML disease remission (AML-CR) cohort, AML-NR displayed distinct cellular interactions and alterations in the ratios of CD4<jats:sup>+<\/jats:sup>T, Treg, and CD8<jats:sup>+<\/jats:sup>T cell populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our findings indicate that the E3 ubiquitin ligase RNF149 accelerates AML progression, modifies the AML immune milieu, triggers CD8<jats:sup>+<\/jats:sup>T cell dysfunction, and influences the transformation of CD8<jats:sup>+<\/jats:sup> Navie.T cells to CD8<jats:sup>+<\/jats:sup>T<jats:sub>Exh<\/jats:sub>, culminating in diminished AML responsiveness to chemotherapeutic agents. Experiments both in vivo and in vitro revealed RNF149\u2019s role in enhancing AML drug-resistant cell line proliferation and in apoptotic inhibition, fostering resistance to Ara-C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In essence, the immune microenvironments of AML-CR and AML-NR diverge considerably, spotlighting RNF149\u2019s tumorigenic function in AML and cementing its status as a potential prognostic indicator and innovative therapeutic avenue for countering AML resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04579-5","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T14:03:30Z","timestamp":1698415410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Xin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongguang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woding","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunmei","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-7547","authenticated-orcid":false,"given":"Qiangqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"4579_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"4579_CR2","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.","journal-title":"BMJ"},{"key":"4579_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36:13\u201322.","journal-title":"Leukemia"},{"key":"4579_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/haematol.2021.280161","volume":"107","author":"JM Rowe","year":"2022","unstructured":"Rowe JM. The 7 + 3 regimen in acute myeloid leukemia. Haematologica. 2022;107:3.","journal-title":"Haematologica"},{"key":"4579_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29.","journal-title":"J Hematol Oncol"},{"key":"4579_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/ijms24010563","volume":"24","author":"KA Skelding","year":"2022","unstructured":"Skelding KA, Barry DL, Theron DZ, Lincz LF. Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia. Int J Mol Sci. 2022;24:563.","journal-title":"Int J Mol Sci"},{"key":"4579_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-022-00316-8","volume":"11","author":"JN Wang","year":"2022","unstructured":"Wang JN, Gu T, Hu Y, Huang H. Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. Exp Hematol Oncol. 2022;11:61.","journal-title":"Exp Hematol Oncol"},{"key":"4579_CR8","doi-asserted-by":"publisher","first-page":"967076","DOI":"10.3389\/fimmu.2022.967076","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Deng Z, Zhao Q. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: a bibliometric study. Front Immunol. 2022;13:967076.","journal-title":"Front Immunol."},{"key":"4579_CR9","doi-asserted-by":"publisher","first-page":"789914","DOI":"10.3389\/fimmu.2021.789914","volume":"12","author":"A Du","year":"2021","unstructured":"Du A, Wu X, Gao Y, et al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in acute myeloid leukemia. Front Immunol. 2021;12:789914.","journal-title":"Front Immunol"},{"key":"4579_CR10","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/cancers13215319","volume":"13","author":"M Ciciarello","year":"2021","unstructured":"Ciciarello M, Corradi G, Forte D, Cavo M, Curti A. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: tangle or chance? Cancers (Basel). 2021;13:5319.","journal-title":"Cancers (Basel)"},{"key":"4579_CR11","doi-asserted-by":"publisher","first-page":"e896","DOI":"10.1097\/HS9.0000000000000896","volume":"7","author":"C Tomasoni","year":"2023","unstructured":"Tomasoni C, Pievani A, Rambaldi B, Biondi A, Serafini M. A question of frame: the role of the bone marrow stromal niche in myeloid malignancies. Hemasphere. 2023;7:e896.","journal-title":"Hemasphere"},{"key":"4579_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li J, Xu L, Gaman MA, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: from biology to therapeutic targeting. Cell Death Discov. 2022;8:397.","journal-title":"Cell Death Discov"},{"key":"4579_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers15041219","volume":"15","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wang Z, Li Y, et al. The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies. Cancers (Basel). 2023;15:12.","journal-title":"Cancers (Basel)"},{"key":"4579_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"4579_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12951-021-01206-7","volume":"20","author":"D Jiang","year":"2022","unstructured":"Jiang D, Wu X, Sun X, et al. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11. J Nanobiotechnol. 2022;20:29.","journal-title":"J Nanobiotechnol"},{"key":"4579_CR16","doi-asserted-by":"publisher","first-page":"105364","DOI":"10.1016\/j.jsbmb.2019.04.013","volume":"191","author":"SH Shahoei","year":"2019","unstructured":"Shahoei SH, Nelson ER. Nuclear receptors, cholesterol homeostasis and the immune system. J Steroid Biochem Mol Biol. 2019;191:105364.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4579_CR17","doi-asserted-by":"publisher","first-page":"e147276","DOI":"10.1172\/JCI147276","volume":"131","author":"SM Gysler","year":"2021","unstructured":"Gysler SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest. 2021;131:e147276.","journal-title":"J Clin Invest."},{"key":"4579_CR18","doi-asserted-by":"publisher","first-page":"110868","DOI":"10.1016\/j.intimp.2023.110868","volume":"124","author":"A Du","year":"2023","unstructured":"Du A, Yang Q, Sun X, Zhao Q. Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression. Int Immunopharmacol. 2023;124:110868.","journal-title":"Int Immunopharmacol"},{"key":"4579_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo R, Lu M, Cao F, et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9:15.","journal-title":"Biomark Res"},{"key":"4579_CR20","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1038\/s41467-019-11591-1","volume":"10","author":"AA Petti","year":"2019","unstructured":"Petti AA, Williams SR, Miller CA, et al. A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing. Nat Commun. 2019;10:3660.","journal-title":"Nat Commun"},{"key":"4579_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/ijms23010361","volume":"23","author":"SY Wang","year":"2021","unstructured":"Wang SY, Shih YH, Shieh TM, Tseng YH. Proteasome inhibitors interrupt the activation of non-canonical NF-kappaB signaling pathway and induce cell apoptosis in cytarabine-resistant HL60 cells. Int J Mol Sci. 2021;23:361.","journal-title":"Int J Mol Sci"},{"key":"4579_CR22","doi-asserted-by":"publisher","first-page":"102798","DOI":"10.1016\/j.jbc.2022.102798","volume":"299","author":"Q Shang","year":"2023","unstructured":"Shang Q, Pan C, Zhang X, et al. Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine. J Biol Chem. 2023;299:102798.","journal-title":"J Biol Chem"},{"key":"4579_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1101\/gad.349368.122","volume":"36","author":"JP Bewersdorf","year":"2022","unstructured":"Bewersdorf JP, Abdel-Wahab O. Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes Dev. 2022;36:259\u201377.","journal-title":"Genes Dev"},{"key":"4579_CR24","doi-asserted-by":"publisher","first-page":"1108200","DOI":"10.3389\/fimmu.2023.1108200","volume":"14","author":"B Aru","year":"2023","unstructured":"Aru B, Pehlivanoglu C, Dal Z, Dereli-Caliskan NN, Gurlu E, Yanikkaya-Demirel G. A potential area of use for immune checkpoint inhibitors: targeting bone marrow microenvironment in acute myeloid leukemia. Front Immunol. 2023;14:1108200.","journal-title":"Front Immunol"},{"key":"4579_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265-81e24.","journal-title":"Cell"},{"key":"4579_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-020-00941-y","volume":"13","author":"J Wu","year":"2020","unstructured":"Wu J, Xiao Y, Sun J, et al. A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol. 2020;13:128.","journal-title":"J Hematol Oncol"},{"key":"4579_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-022-01755-2","volume":"37","author":"VY Ling","year":"2023","unstructured":"Ling VY, Straube J, Godfrey W, et al. Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia. 2023;37:143\u201353.","journal-title":"Leukemia"},{"key":"4579_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clml.2019.12.007","volume":"20","author":"P Dhakal","year":"2020","unstructured":"Dhakal P, Pyakuryal B, Pudasainee P, Rajasurya V, Gundabolu K, Bhatt VR. Treatment strategies for therapy-related acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:147\u201355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4579_CR29","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, Bucklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"4579_CR30","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/cells10123376","volume":"10","author":"F Hao","year":"2021","unstructured":"Hao F, Sholy C, Wang C, Cao M, Kang X. The role of T cell immunotherapy in acute myeloid leukemia. Cells. 2021;10:3376.","journal-title":"Cells"},{"key":"4579_CR31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019961","author":"J Vadakekolathu","year":"2023","unstructured":"Vadakekolathu J, Rutella S. Escape from T-cell targeting immunotherapies in acute myeloid leukemia. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2023019961.","journal-title":"Blood"},{"key":"4579_CR32","doi-asserted-by":"publisher","first-page":"1139517","DOI":"10.3389\/fimmu.2023.1139517","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zheng H, Zhu Y, et al. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia. Front Immunol. 2023;14:1139517.","journal-title":"Front Immunol"},{"key":"4579_CR33","doi-asserted-by":"publisher","first-page":"4024887","DOI":"10.1155\/2023\/4024887","volume":"2023","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Tan S, Wang H, et al. Mesenchymal stem cell-derived exosomal miRNA-222-3p increases Th1\/Th2 ratio and promotes apoptosis of acute myeloid leukemia cells. Anal Cell Pathol. 2023;2023:4024887.","journal-title":"Anal Cell Pathol"},{"key":"4579_CR34","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","volume":"120","author":"J Greiner","year":"2012","unstructured":"Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood. 2012;120:1282\u20139.","journal-title":"Blood"},{"key":"4579_CR35","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1182\/blood.2022017795","volume":"141","author":"JC Rimando","year":"2023","unstructured":"Rimando JC, Chendamarai E, Rettig MP, et al. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells. Blood. 2023;141:1718\u201323.","journal-title":"Blood"},{"key":"4579_CR36","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139:3594\u2013604.","journal-title":"Blood"},{"key":"4579_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nsmb.2780","volume":"21","author":"CE Berndsen","year":"2014","unstructured":"Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol. 2014;21:301\u20137.","journal-title":"Nat Struct Mol Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04579-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04579-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04579-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T14:09:47Z","timestamp":1698415787000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04579-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4579"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04579-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Qinghai Provincial People\u2019s Hospital, and informed consent was obtained from each patient (ethical approval number: 2022-66).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"760"}}